Two therapies for immune-mediated inflammatory disease

Risankizumab vs upadacitinib: trial pipelines compared

A side-by-side view of the risankizumab and upadacitinib clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for risankizumab and 16+ for upadacitinib. Add up to three more drugs to widen the comparison.

risankizumab (16) vs upadacitinib (16)16 active2015–2032

Hide completed

risankizumabupadacitinib

Key

Actual date

Anticipated

Forecast to primary completion

RecruitingActive, not recruitingNot yet recruitingCompletedUnknown status

'15

'17

'19

'21

'23

'25

'27

'29

'31

risankizumab

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisP3

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentP3

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisP3

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic TreatmentP3

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative ColitisP2

COMMANDP3

DETERMINED 1P2

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or IxekizumabP3

PSORIASI_RISAP4

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic TherapyP4

SOPRANO-CDP4

UnlIMMitedP4

AFFIRMP3

IZAR-2P3

Risankizumab for Fibrostenotic Crohn's Disease TreatmentP3

CHARGEP3

upadacitinib

SELECT-COMPAREP3

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)P3

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic DermatitisP2

U-ACTIVATEP3

SELECT - PsA 1P3

SELECT - PsA 2P3

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)P3

AD UpP3

DOPPLERP3

COVERP4

Flex-UpP4

Step-Up HSP3

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative ColitisP4

Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's DiseaseP4

Start UpP3

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）P4

Upcoming readouts

12 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Head to head

Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.

risankizumab (Skyrizi)Immunology & inflammation

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Jan 2027

Next phase 3 readout

upadacitinib (Rinvoq)Immunology & inflammation

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Jul 2027

Next phase 3 readout

Key trials across both drugs

Top 16 registered phase 2–4 trials across risankizumab and upadacitinib, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.

Drug	Trial	Title	Phase	Status	Primary completion
upadacitinib	NCT06520397	Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensifie…	Phase 4	Recruiting	Dec 2026
risankizumab	NCT05169593	SOPRANO-CD: Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biolog…	Phase 4	Recruiting	Oct 2027
upadacitinib	NCT05867329	Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcer…	Phase 4	Recruiting	Nov 2027
upadacitinib	NCT07550673	Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRI…	Phase 4	Recruiting	Apr 2028
risankizumab	NCT04908475	Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Chang…	Phase 4	Completed	Apr 2023
upadacitinib	NCT05080218	COVER: COVID-19 VaccinE Response in Rheumatology Patients	Phase 4	Completed	Apr 2024
upadacitinib	NCT05507580	Flex-Up: A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult P…	Phase 4	Completed	Jul 2024
risankizumab	NCT05969223	UnlIMMited: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Partici…	Phase 4	Completed	Jan 2025
risankizumab	NCT04722640	PSORIASI_RISA: Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity	Phase 4	Unknown	Jan 2022
risankizumab	NCT07499232	CHARGE: A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Cro…	Phase 3	Recruiting	Nov 2028
upadacitinib	NCT06461897	Start Up: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to S…	Phase 3	Recruiting	Jul 2030
upadacitinib	NCT02629159	SELECT-COMPARE: A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid …	Phase 3	Active, not recruiting	Oct 2017
upadacitinib	NCT03568318	AD Up: A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and A…	Phase 3	Active, not recruiting	Feb 2021
risankizumab	NCT06641089	IZAR-2: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate R…	Phase 3	Active, not recruiting	Jan 2027
risankizumab	NCT06063967	AFFIRM: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Ind…	Phase 3	Active, not recruiting	Mar 2027
upadacitinib	NCT03006068	U-ACTIVATE: A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants …	Phase 3	Active, not recruiting	Jul 2027

Track risankizumab and upadacitinib with ComplyRx

Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.

Track both drugs

FAQ

How do the risankizumab and upadacitinib clinical pipelines compare?: ClinicalTrials.gov currently lists 16+ phase 2–4 trials for risankizumab and 16+ for upadacitinib. The timeline above plots both side by side and refreshes daily.
Where does this data come from?: All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
Can I add more drugs to the comparison?: Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.

Upcoming readouts

Head to head

Key trials across both drugs

Track risankizumab and upadacitinib with ComplyRx

Individual pipelines and other comparisons

FAQ

Keep followingwhat matters.

Keep following
what matters.